1. Home
  2. BIOX vs GLSI Comparison

BIOX vs GLSI Comparison

Compare BIOX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIOX
  • GLSI
  • Stock Information
  • Founded
  • BIOX 2001
  • GLSI 2006
  • Country
  • BIOX Argentina
  • GLSI United States
  • Employees
  • BIOX N/A
  • GLSI N/A
  • Industry
  • BIOX Agricultural Chemicals
  • GLSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • BIOX Industrials
  • GLSI Health Care
  • Exchange
  • BIOX Nasdaq
  • GLSI Nasdaq
  • Market Cap
  • BIOX 168.3M
  • GLSI 134.6M
  • IPO Year
  • BIOX N/A
  • GLSI 2020
  • Fundamental
  • Price
  • BIOX $2.77
  • GLSI $11.48
  • Analyst Decision
  • BIOX Strong Buy
  • GLSI Strong Buy
  • Analyst Count
  • BIOX 4
  • GLSI 1
  • Target Price
  • BIOX $8.38
  • GLSI $39.00
  • AVG Volume (30 Days)
  • BIOX 279.5K
  • GLSI 44.0K
  • Earning Date
  • BIOX 09-08-2025
  • GLSI 08-14-2025
  • Dividend Yield
  • BIOX N/A
  • GLSI N/A
  • EPS Growth
  • BIOX N/A
  • GLSI N/A
  • EPS
  • BIOX N/A
  • GLSI N/A
  • Revenue
  • BIOX $383,289,394.00
  • GLSI N/A
  • Revenue This Year
  • BIOX N/A
  • GLSI N/A
  • Revenue Next Year
  • BIOX $7.30
  • GLSI N/A
  • P/E Ratio
  • BIOX N/A
  • GLSI N/A
  • Revenue Growth
  • BIOX N/A
  • GLSI N/A
  • 52 Week Low
  • BIOX $2.60
  • GLSI $8.06
  • 52 Week High
  • BIOX $11.39
  • GLSI $16.50
  • Technical
  • Relative Strength Index (RSI)
  • BIOX 35.91
  • GLSI 48.08
  • Support Level
  • BIOX $2.63
  • GLSI $11.35
  • Resistance Level
  • BIOX $2.89
  • GLSI $12.07
  • Average True Range (ATR)
  • BIOX 0.19
  • GLSI 0.57
  • MACD
  • BIOX 0.02
  • GLSI -0.12
  • Stochastic Oscillator
  • BIOX 30.77
  • GLSI 8.78

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: